NEW YORK (GenomeWeb News) – Curetis and Cempra today announced a collaboration for the use of Curetis' Unyvero molecular diagnostic system in Cempra's phase III trial for its oral drug for community-acquired bacterial pneumonia.

Cempra expects to enroll more than 800 patients for the trial, which will compare its solithromyrin oral formulation against a comparator drug in more than 100 clinical sites globally. Samples of sputum will be sent to Curetis for analysis with its Unyvero Solution and Unyvero P50 Pneumonia Application Cartridge.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.